Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

• Status: Terminated
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Camptothecin; Irinotecan

Criteria

Inclusion Criteria:

• Advanced solid tumors for which standard treatment doesn't exist or is no longer effective.

• Must be suitable for treatment with irinotecan

• Relatively good overall health other than your cancer

Exclusion Criteria:

• Poor bone marrow function (not producing enough blood cells)

• Serious heart conditions

• Poor liver or kidney function

• Any prior anthracycline treatment